UltiMed, Inc. announces expansion of U.S. pen needle manufacturing

  • December 15, 2010
  • Corporate News

St. Paul, MN – December 14, 2010 – UltiMed, Inc. announced the completion of the installation of its new, fully automated pen needle packaging machine.

Without full automation, the counting and packaging of UltiMed’s dual use packaging style was labor intensive. With the addition of the new fully automated packaging machinery, the counting and packaging of pen needles, including case sealing, can be done at a rapid rate with just one operator.

UltiMed, Inc., headquartered in St. Paul, Minnesota, manufactures diabetic drug delivery and specialty safety syringe devices, including insulin syringes, pen needles and specialty safety syringes for both the domestic and international markets. The company owns and operates two state of the art medical device-manufacturing facilities in the U.S. and abroad. UltiMed, Inc. has a wide range of global business partners to assist in bringing its broad spectrum of medical products to customers around the world. UltiMed, Inc. is a leader in safe needle disposal, and offers their full-line of diabetic insulin syringes and pen needles in a patented UltiGuard™ dual- use packaging style. The exclusive packaging style combines premium quality needles and an approved sharps container all in one system.

UltiMed, Inc. introduces new Tuberculin Safety Syringe line

  • November 04, 2010
  • Corporate News

St. Paul, MN – November 3, 2010 – UltiMed, Inc. announced today the introduction of the new UltiCare® Tuberculin Safety Syringe line.

The UltiCare safety-engineered tuberculin syringes are a premium quality, low-cost alternative that protect both the patient and healthcare provider. The low dead space design technology reduces medication waste and cost by precisely and accurately delivering each dose. The introduction of the UltiCare Tuberculin Safety Syringe fills a void in a competitive market and offers customers an alternative safety tuberculin syringe. UltiMed, Inc. continues to be an innovative leader in specialty low dead space syringe development.

UltiMed, Inc., headquartered in St. Paul, Minnesota, manufactures diabetic drug delivery and specialty safety syringe devices, including insulin syringes, pen needles and specialty safety syringes for both the domestic and international markets. The company owns and operates two state of the art medical device-manufacturing facilities in the U.S. and abroad. UltiMed, Inc. has a wide range of global business partners to assist in bringing its broad spectrum of medical products to customers around the world. UltiMed, Inc. is a leader in safe needle disposal, and offers their full-line of diabetic insulin syringes and pen needles in a patented UltiGuard™ dual- use packaging style. The exclusive packaging style combines premium quality needles and an approved sharps container all in one system.

UltiMed, Inc. announces addition of Brahim Zabeli as Vice President of US Diabetes

  • September 25, 2010
  • Corporate News

St. Paul, MN – September 24, 2010 – Brahim Zabeli joins UltiMed, Inc. as Vice President of U.S. Diabetes Care.

UltiMed, Inc. announced today that Brahim Zabeli has joined the team as Vice President of U.S. Diabetes Care. Mr. Zabeli comes to UltiMed, Inc. from the world market leader in syringes and pen needles, Becton Dickinson (BD) (ticker: BDX). At BD, Mr. Zabeli was the Director of U.S. Retail Sales & Managed Markets. He was also a member of the BD Diabetes Care Global Extended Leadership Team. In the U.S. market, Mr. Zabeli’s team developed and implemented plans which grew the core insulin delivery business to 83% market share. Mr. Zabeli was directly involved in the successful contract negotiations with key strategic customers, including: Caremark, CVS, Walgreen’s, Walmart and Target. Prior to BD, Mr. Zabeli held positions of VP Sales & Marketing, Area Manager, National Account Manager, Account Representative and Division Manager at Arkray USA (fka (Hypoguard), LifeScan (a Johnson & Johnson Company), and Pfizer Consumer Health (fkaWhitehall-Robins Healthcare/ Wyeth Consumer Healthcare. Mr. Zabeli has a BA from State University of New York at Buffalo and an MBA from The Claremont Graduate University.

In his new capacity, Zabeli will oversee all marketing and sales management programs for U.S. Diabetes Care division.

UltiMed, Inc., headquartered in St. Paul, Minnesota, manufactures diabetic drug delivery and specialty safety syringe devices, including insulin syringes, pen needles and specialty safety syringes for both the domestic and international markets. The company owns and operates two state of the art medical device-manufacturing facilities in the U.S. and abroad. UltiMed, Inc. has a wide range of global business partners to assist in bringing its broad spectrum of medical products to customers around the world. UltiMed, Inc. is a leader in safe needle disposal, and offers their full-line of diabetic insulin syringes and pen needles in a patented UltiGuard™ dual- use packaging style. The exclusive packaging style combines premium quality needles and an approved sharps container all in one system.